Red Tree Venture Capital Closes Inaugural Fund, at $272M

Red Tree Venture CapitalRed Tree Venture Capital Fund I, a West Coast-based, early stage-biased, life science venture capital company, has closed its $272 million final close.

Red Tree was established in 2020 by Heath Lukatch, Ph.D., and Jennifer Cochran. The firm invests in West Coast innovation. The group leverages relationships with scientific luminaries and serial entrepreneurs at the region’s leading institutions to source opportunities focused on first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology, neurology, and immunology.

Red Tree has already committed part of its new fund to investment in ten companies. Each company is at the forefront for scientific innovation within their field.

To date, Red Tree’s portfolio includes:

  • Acrigen Biosciences
  • Alladapt Immunotherapeutics
  • Ceribell
  • Excellergy Therapeutics
  • Magnus Medical
  • Pipeline Therapeutics
  • Rondo Therapeutics
  • Sardona Therapeutics
  • Syncopation Life Sciences
  • Virsti Therapeutics

Red Tree founder Krishna Polu M.D., a seasoned drug developer, rounds out the team



Leave a Comment